sore arm; decreased appetite; weight loss; sluggish; cough; vomiting; occasional constipation/diarrhea; occasional constipation/diarrhea; runny nose with blood tinged mucus; hip/lower back pain; taste changes; hip/lower back pain; slipped on stairs; This is a spontaneous report from a contactable consumer, based on information received by Pfizer from (manufacturer control number: EC-2020-085992), for bnt162b2. A 60-years-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as dose 2, single for covid-19 immunization; lenvatinib mesilate (LENVIMA), oral from 14Dec2020 (Batch/Lot number was not reported) to Feb2021, at 12 mg, 1x/day, oral from Mar2021 (Batch/Lot number was not reported) to Apr2021, at unspecified dose, oral from 05May2021 (Batch/Lot number was not reported) and ongoing, at UNK UNK, alternate day for renal cancer; everolimus (EVEROLIMUS), oral from 14Dec2020 (Batch/Lot number was not reported) to Feb2021, at 5 mg, 1x/day, oral from Mar2021 (Batch/Lot number was not reported) to Apr2021, at unspecified dose, oral from 05May2021 (Batch/Lot number was not reported) to an unspecified date, at UNK UNK, alternate day for renal cancer. Medical history included radiotherapy from Feb2021 to an unknown date. The patient's concomitant medications were not reported. It was reported that Patient began med 14Dec2020 taking Lenvima 12 mg/QD with Everolimus 5 mg/QD. Placed on hold Feb2021 for rash and Everolimus decreased to every other day. Restarted both Mar2021 after radiation Feb2021 as previously reported. On hold again Apr2021 for about 10 days and restarted 05May2021 taking each med every other day for now, same dose. Patient reported decreased appetite with weight loss, feeling sluggish, increased coughing/increased mucous with vomiting at times, occasional constipation/diarrhea, runny nose with blood tinged mucus at times, slipped on stairs recently and now with hip/lower back pain slowly improving, taste changes, recent scan stable except for some increased growth noted in lumbar and neck area, sore arm after 2nd Covid vaccine 2 weeks ago but better now. Patient missed 1 day of med when he fell asleep and MD placed Lenvima on hold 10 days and added Prednisone so pt could gain some weight which seems to be helping. Pt's activity less due to recent fall and weight loss but able to carry out light house work, has difficulty with strenuous activities. Next MD appointment 01Jun2021. MD aware of all issues. The patient underwent lab tests and procedures which included scan: stable except for some increased growth noted in l   on stable except for some increased growth noted in lumbar and neck area, sore arm, weight: loss. The action taken in response to the event(s) for bnt162b2 was not applicable, for lenvatinib mesilate was temporarily withdrawn on an unspecified date, for everolimus was temporarily withdrawn on an unspecified date. Therapeutic measures were taken as a result of weight loss (weight decreased). The outcome of the event for sore arm, decreased appetite with weight loss, feeling sluggish, increased coughing/increased mucous with vomiting, hip/lower back pain, slipped on stairs was recovering, and for rest all event was unknown.